Madrigal said that all patients enrolled in MAESTRO-NASH - which include up to 2,000 in total - are continuing on therapy after the initial 52-week treatment period.

If resmetirom hits the mark in the upcoming MAESTRO-NASH trial, Madrigal could leapfrog rival developers and bring the first drug to market for the treatment of patients with NASH and liver ...

Corebridge Financial Inc. reduced its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 4.7% during ...

Madrigal became the victor in the so-called "NASH-Dash" when its candidate resmetirom, a "once-daily, oral, liver-directed THR-β agonist" was approved, under the brand name Rezdiffra, in March ...

This guidance, along with data from the open-label compensated MASH cirrhosis arm of MAESTRO-NAFLD-1, informed the design of the ongoing Phase 3 MAESTRO-NASH OUTCOMES trial. Madrigal plans to ...

Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has been making waves in the biopharmaceutical industry with its flagship product, Rezdiffra, a treatment for non-alcoholic steatohepatitis (NASH).

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has been making waves in the biopharmaceutical industry with its flagship product, Rezdiffra, a treatment for non-alcoholic steatohepatitis (NASH). As the ...